Anne wojcicki to buy 23andme and its data for $ 305 million

Anne Wojcicki, co -founder and former CEO of 23andme, has regained control of the besieged genetic test company after its new non -profit institute, TTAM Research, Outbid Regeneron PharmaceuticalsThe company Declare Friday.

TTAM will get all 23ndme assets significantly for $ 305 million, including the personal genome services and research services lines, as well as the remotely affiliated Lemonaid Health Company. It is a great victory for WojCICKI, who stepped from her role as CEO when 23andme Submitted to Chapter 11 Discipline protection in March.

Last month, Regeneron announced that it would buy most of 23ndme assets for $ 256 million after being issued at the forefront during the bankruptcy auction. But WoJCICKI made a separate offer of $ 305 million through TTAM and paid to reopen the auction. TTAM is an acronym for the first messages from 23andme, according to Wall Street Journal.

“I am pleased that the TTAM Research Institute will be able to continue the 23DME mission to help people reach the human genome and benefit from it,” Wogiki said in a statement.

23ndme gained popularity due to the DNA testing groups at home that gave customers an insight into their family history and genetic files. Five times CNBC Disruptor 50 a company Open In 2021, through a merging process with a private purpose acquisition company. At its peak, the value of 23andme was about $ 6 billion.

The company has struggled to generate repeated revenues and to find out life and treatment companies after moving to public places, and it has been afflicted with concerns related to privacy since then The infiltrators arrived at the information Of nearly seven million customers in 2023.

TTAM acquisition is still under approval from the American Banking Court of the Eastern Region in Missouri.